Navigation Links
Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
Date:12/3/2013

SAN DIEGO, Dec. 3, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced a regulatory update after receiving feedback from the U.S. Food and Drug Administration (FDA) on the development of quizartinib (AC220), the Company's lead drug candidate, for the treatment of relapsed/refractory acute myeloid leukemia (AML).

Based on feedback from the FDA, the Company continues to move forward with its baseline plan to conduct a randomized, controlled Phase 3 clinical trial in relapsed/refractory FLT3-ITD positive AML patients with an overall survival endpoint as the basis for the potential initial approval of quizartinib.  The Company is continuing to work with the FDA to refine the appropriate starting dose for the Phase 3 trial. 

The Company has been in dialogue with the FDA related to acceptance of a novel surrogate endpoint that could support accelerated approval based upon the results of the Company's Phase 2 and Phase 2b trials.  The FDA informed the Company it does not agree that complete remission with incomplete hematologic recovery (CRi) represents a surrogate endpoint reasonably likely to predict clinical benefit.  Based on the FDA's current position, the Company does not plan at this time to submit a NDA for accelerated approval of quizartinib based on the Phase 2 and 2b clinical trial data.

"We remain committed to moving quizartinib through its late stage development as expeditiously as possible, given the limited treatment options for FLT3 ITD positive AML patients who have relapsed or who are refractory to prior treatments.  We will continue to work with the clinical community and the FDA to achieve this goal," said

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
2. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
3. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
4. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
5. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
6. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
7. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
8. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
9. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
10. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
11. Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Kindred Hospital Houston Northwest, with ... opening of its new outpatient wound healing center.  ... people with chronic, hard to heal wounds. Chronic ... to amputation, lower leg wounds related to blood ... and traumatic injury wounds which are complex and ...
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... DIEGO , May 5 Volcano Corporation (Nasdaq: VOLC ... designed to enhance the diagnosis and treatment of coronary and peripheral vascular ... America Merrill Lynch Health Care Conference on Tuesday, May 11 . ... The presentation by ...
... , ABBOTT PARK, Ill., May 5 Abbott (NYSE: ... on Friday, June 4, 2010 in New York City . ... on the company at 9 a.m. Central time . , ... A live audio webcast of the presentation will be ...
Cached Medicine Technology:Volcano Corporation Presentation at Bank of America Merrill Lynch Health Care Conference to Be Webcast 2
(Date:7/14/2014)... New research and analysis from the national ... examines toxic ingredients in tampons, a product used ... chemicals that may be found in the product’s absorptive ... put women’s health at risk. , According to ... , the potential impact of toxic chemical exposure from ...
(Date:7/13/2014)... (PRWEB) July 14, 2014 FORT LEE, N.J. ... tackle the modern approach to the science of tooth ... Implant. This book describes recent advances and techniques ... methodological approaches that benefit people who have lost all of ... inserted the first lower subperiosteal implant in 1940. ...
(Date:7/13/2014)... MA (PRWEB) July 14, 2014 MED-Ed ... presenting at our next conference, April 7+8 in Boston ... well attended at the recent event. Presentations by individuals ... 2014. , To review the types of sessions that ... , Submit your proposal today! , Conference ...
(Date:7/13/2014)... 14, 2014 Worldwide ladies are extremely ... Angeldress.co.uk has taken a different approach and has created ... are offered in more colour choices that responded directly ... brand of women’s special occasion apparels. The company’s pink ... specialists are working hard to create the best products ...
(Date:7/13/2014)... July 13, 2014 Ticket Down ... Madrid Tickets . For the fifth straight year (and ... will be held at American stadiums this summer. The tournament ... American soil. The eight teams are split into two groups ... the top two teams will compete to become champion. One ...
Breaking Medicine News(10 mins):Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 4Health News:MED-Ed Facilities Conference Call for Speakers Open 2Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3
... Genomatix Software Inc., the newly incorporated subsidiary of Genomatix Software ... software licensing agreement with the NCI/NIH for the fourth consecutive ... history as the renewal was executed entirely between the US ... We are extremely pleased with our progress in putting the ...
... Rice University Psychology Professor Tony Ro has published its ... as synesthesia, in which stimulation of one sensory pathway ... pathway. , Ro,s paper, Feeling Sounds After a Thalamic ... the official journal of the American Neurological Association. The ...
... - Researchers at the Centre for Addiction and Mental ... and the risk of head and neck cancers, showing ... cancer risk. , According to CAMH Principal Investigator ... between alcohol consumption and an increased risk for cancer ...
... Drug Discovery Projects, REDWOOD CITY, Calif., Sept. ... announced today that it has obtained,commitments from several ... its common stock and warrants to purchase,approximately 2.6 ... proceeds of,approximately $23.7 million. The investors have agreed ...
... form of care, experts say , WEDNESDAY, Sept. ... issued new "performance measures" meant to boost patient enrollment ... heart attack patients aren,t getting the benefit of this ... set standards of excellence for these programs and are ...
... The close of summer traditionally,marks the return to ... fall,and holiday baking seasons. This year, in response to ... cooking is a growing,trend. A study published in the ... in kids, body mass index occur during the summer,months, ...
Cached Medicine News:Health News:Research at Rice may help explain aspects of synesthesia 2Health News:Research at Rice may help explain aspects of synesthesia 3Health News:Alcohol and cancer: is drinking the new smoking? 2Health News:Genelabs Technologies Announces Commitments to Raise $23.7 Million in a Registered Direct Financing 2Health News:Heart Attack Survivors Benefit From Rehab 2Health News:Just in Time for Fall Baking and Entertaining: The Sneaky Chef Tips Featuring Eagle Mills All-Purpose Flour made with Ultragrain(R) 2Health News:Just in Time for Fall Baking and Entertaining: The Sneaky Chef Tips Featuring Eagle Mills All-Purpose Flour made with Ultragrain(R) 3Health News:Just in Time for Fall Baking and Entertaining: The Sneaky Chef Tips Featuring Eagle Mills All-Purpose Flour made with Ultragrain(R) 4
... complete line of enteric disease ... and monoclonal/polyclonal antibody-based ELISA tests ... pathogens in fecal specimens. Our ... difficile, Entamoeba histolytica, Giardia, Cryptosporidium ...
... II test is also available with Inverness ... greatly reduces the hands-on time required to ... testing. The Fecal-Quik-Prep device is a unique ... amount of hands-on time required to prepare ...
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: